Open AccessDetermination of blood dexmedetomidine in dried blood spots by LC-MS/MS to screen therapeutic levels in paediatric patients
Author(s) -
Liliana Rivera-Espinosa,
Alejandra Toledo-López,
Juan Luis ChávezPacheco,
Radamés Alemón-Medina,
Josefina Gómez-Garduño,
Gustavo Lugo-Goytia,
Raquel García-Álvarez,
Hugo Juárez-Olguı́n,
Luz María TorresEspíndola,
María-Gabriela Pérez-Guillé
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0210391
Subject(s) - dexmedetomidine , formic acid , chromatography , dried blood spot , therapeutic drug monitoring , sedation , spots , pharmacokinetics , chemistry , liquid chromatography–mass spectrometry , extraction (chemistry) , tandem mass spectrometry , mass spectrometry , medicine , anesthesia , pharmacology
Dexmedetomidine is an imidazole derivative, with high affinity for α2 adrenergic receptors, used for sedation, analgesia and adjuvant anaesthesia. In this study, an analytical method for the quantification of dexmedetomidine in dried blood spots was developed, validated and applied. The drug was extracted from dried blood spot by liquid extraction; the separation was carried out by ultra high-resolution liquid chromatography in reverse phase coupled to tandem mass spectrometry method. An X Select cyano 5 μm HSS column (2.1 X 150 mm, Waters) and a mobile phase composed of 0.1% formic acid: acetonitrile [50:50 v/v], were used. The test was linear over the concentration range of 50 to 2000 pg/mL. The coefficients of variation for the intra and interday trials were less than 15%. The drug was stable under the conditions tested. The method was successfully applied for the quantification of 6 patients, aged 0 to 2 years, with classification ASA I, who underwent ambulatory surgeries, receiving a dose of 1 μg/Kg dexmedetomidine IV. The drug concentrations in the different sampling times were in the range of 76 to 868 pg/mL.